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This multicenter study evaluated the clinical performance of the 3M Rapid Detection RSV test (3MRSV)
compared to a composite reference standard of R-Mix culture and direct specimen immunofluorescence for
detection of respiratory syncytial virus (RSV). The performance of the BinaxNOW RSV test was also
evaluated using this reference standard. In a secondary analysis, discordant results were arbitrated using
the Gen-Probe/Prodesse ProFluⴙ reverse transcription-PCR (RT-PCR) assay. Subjects were stratified into
three groups as follows: group 1 (G1), all ages; G2, subjects <22 years old (FDA-cleared ages for 3MRSV
testing); and G3, subjects <5 years old (FDA-cleared ages for BinaxNOW RSV testing). A total of 1,306
specimens (G1, n ⴝ 1,306; G2, n ⴝ 1,140; G3, n ⴝ 953) from subjects of all ages presenting with respiratory
symptoms met study criteria for analysis. Sensitivities, specificities, positive predictive values, and negative
predictive values of 3MRSV for G1 were 86.5%, 95.8%, 91.4%, and 93.2%, respectively, and those for G2 were
87.3%, 95.6%, 92.4%, and 92.5%, respectively. For those samples analyzed by both 3MRSV and BinaxNOW, the
3MRSV was more sensitive (G1, 86.3%; G2, 87.2%; and G3, 89.9%) than was BinaxNOW (G1, 70.84%; G2,
72.0%; and G3, 72.4%) (P < 0.05). Specificities for RSV detection from nasopharyngeal (NP) aspirates and NP
swabs for all groups were comparable for 3MRSV and BinaxNOW, but 3MRSV was less specific than
BinaxNOW when nasal washes/aspirates were tested (P < 0.05). The 3MRSV assay performed well for the
detection of RSV, and the overall assay performance was superior to that of BinaxNOW. The 3MRSV reader
eliminated user misinterpretation and provided test result and quality control documentation.
signs and symptoms alone is inaccurate (15). Antigen detection
methods such as rapid membrane immunoassays offer the advantages of a rapid time to results (generally 15 to 30 min) and
relative ease of use but are less sensitive than direct specimen
immunofluorescent-antigen testing (DSFA) of respiratory epithelial cells, viral culture, and nucleic acid amplification tests
(10, 11). Nevertheless, rapid antigen tests allow for RSV testing in clinical settings that lack the laboratory support for these
more complex tests.
The performance of rapid immunoassays and thus the clinical utility of test results are influenced by a variety of factors,
including specimen type, specimen collection method, timing
of specimen collection relative to onset of symptoms, and patient age. Children shed higher titers of virus for longer time
periods than adults; thus, rapid immunoassays are more sensitive in the pediatric population, particularly in children ⬍5
years of age (2, 4, 7, 10). Additional factors affecting rapid test
performance and utility include the subjective visual interpretation of results and low positive predictive values when testing
is performed during periods of low disease prevalence (10).
This study was a prospective, multicenter, premarket clinical
trial designed to establish the performance of the 3M Rapid
Detection RSV test (3MRSV) (3M Health Care, Saint Paul,
MN) for U.S. Food and Drug Administration (FDA) clearance
as an in vitro diagnostic device. The 3MRSV is a qualitative
immunochromatographic cartridge test for the detection of
RSV in nasal aspirate/wash and nasopharyngeal aspirate/swab

Respiratory syncytial virus (RSV) is the most common cause
of bronchiolitis and pneumonia associated with hospital admissions in children younger than 1 year old (14). In addition,
RSV is responsible for significant morbidity in older infants
and young children, the elderly, and the immunocompromised
(5, 8, 16). RSV is also associated with substantial morbidity in
infants and children in an outpatient setting (9). Hall et al.
estimated that RSV infection in children under the age of 5
years results in 1 of 334 hospitalizations, 1 of 38 visits to an
emergency department, and 1 of 13 visits to a primary care
provider each year in the United States (9). When populationbased data were extrapolated to the entire U.S. population,
these authors estimated that 2.1 million children under 5 years
of age with RSV infection would have medical attention each
year. Moreover, a hallmark of RSV infection is that a single
infection does not confer lifelong immunity resulting in reinfection throughout life (8). Thus, RSV imposes a substantial
burden of disease, particularly in the pediatric population.
Accurate diagnosis depends on detection of RSV in respiratory tract specimens, because differentiation of RSV infection from other viral respiratory infections based on clinical
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specimens. 3MRSV results were compared to results of DSFA,
viral culture, and another rapid antigen test, the BinaxNOW
RSV test (Binax, Inverness Medical, Waltham, MA).
After completion of this study, the 3M Rapid Detection
RSV test received clearance from the FDA as an in vitro
diagnostic assay for the detection of RSV F protein antigens in
nasopharyngeal aspirate/swab specimens and nasal aspirate/
wash specimens in symptomatic patients less than 22 years
of age.
(This study was presented in part at the 25th Clinical Virology Symposium, Daytona Beach, FL, 2010.)
MATERIALS AND METHODS
Study subjects. This study was conducted from December 2008 through January 2009, a period of high prevalence of RSV at each of the eight geographically
diverse U.S. clinical trial sites that participated in this study (13). Inclusion
criteria required the presence of at least two of the following symptoms: wheezing, coughing, nasal discharge, nasal congestion, fever (ⱖ100.4°F), and/or rales
on chest exam. A total of 1,501 subjects of all ages were enrolled in the study, 793
females and 707 males, with one gender not reported. Three subject groups were
established: group 1 (G1) (n ⫽ 1,501) consisted of subjects of all ages (range
from 1 week to ⬎89 years), G2 (n ⫽ 1,279) consisted of subjects ⬍22 years old
(the age group cleared by the FDA for testing with 3MRSV), and G3 (n ⫽ 1,064)
consisted of subjects ⬍5 years old (the age group cleared by the FDA for testing
with the BinaxNOW RSV test). The number of subjects (percentage of total) by
various age subgroups was 1,087 (72.4%) for 0 to 5 years, 192 (12.8%) for 6 to
21 years, 131 (8.7) for 22 to 59 years, and 91 (6.1%) for ⱖ60 years. One site
enrolled 28% of the subjects, and the other seven sites each enrolled between 6%
and 13% of the subjects. This study was performed with the approval of each
site’s Institutional Review Board.

Study samples. Samples used for this study consisted of respiratory secretions
submitted to participating laboratories by physician order for routine diagnostic
testing and for which there was residual material destined to be discarded;
samples were deidentified before being made available to study personnel. Only
one sample per subject was permitted. Respiratory samples were collected in
accordance with each site’s standard practice. Sample types included nasal washes/
aspirates (NW/A) (n ⫽ 301 [G1], 285 [G2], and 263 [G3]), nasopharyngeal
aspirates (NPA) (n ⫽ 593 [G1], 570 [G2], and 481 [G3]), nasopharyngeal swabs
(NPS) (n ⫽ 605 [G1], 442 [G2], and 318 [G3]) in viral transport media (UTM,
Diagnostic Hybrids [DHI], Athens, OH [two sites]; M4, Remel, Lenexa, KS
[three sites]; M4RT, Remel [two sites]), and throat swabs (n ⫽ 2 [G3]) in viral
transport media. Flocked swabs (Copan, Murrieta, CA) were used for sample
collection at four of the five sites that collected NPS. NPA were collected using
a catheter inserted into the nose directed posteriorly and toward the opening of
the external ear. Suction was applied, and using a rotating movement, secretions
were collected as the catheter was withdrawn. NW/A were collected by instilling
saline, via a syringe and tubing, into the nostril and aspirating the recoverable
nasopharyngeal specimen. The presence of mucus or blood (slight or excess) in
the sample was noted. Samples were stored at 2 to 8°C if 3MRSV was not
performed within 4 h of sample collection. Upon completion of all required
testing, the remaining excess original sample was frozen in 300-l aliquots at
ⱕ⫺70°C in case discordance analysis was required.
3M Rapid Detection RSV test. The 3MRSV was performed within 72 h of
sample collection and according to the manufacturer’s instructions. Refrigerated
samples were stored at room temperature for 15 min prior to testing. Briefly, 150
l of neat sample was added to a vial containing 150 l of 3MRSV sample buffer.
The neat sample and 3MRSV sample buffer were mixed 10 times using an assay
pipette tip that contains fluorophore-tagged particles coated with anti-RSV antibodies directed against F protein antigens of RSV (Fig. 1). A 75-l aliquot of
the mixture was transferred into the well of a test cartridge and inserted into the
3M rapid detection reader. The sample migrates along the strip contained within
the test cartridge, and anti-F protein antibodies bind to the corresponding RSV
antigens if present. RSV-bound particles are captured at the RSV detection
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FIG. 1. Test procedure for the 3M Rapid Detection RSV test. 1, touch screen rapid detection reader. Sample (2) is added to buffer (3) and
mixed with an assay tip (4) that contains fluorescence-dyed particles conjugated to specific RSV antibodies that bind to RSV F protein antigens,
if present in the sample. The sample is then applied to the sample well of the test cartridge (5), which is inserted into the 3M rapid detection reader
(6). As the sample migrates along the strip, RSV-bound particles are captured by anti-RSV antibodies at the detection zone. Excess fluorescencedyed particles are captured at the internal standard (IS) zone. The reader measures the fluorescence emitted by the complexes at the detection
zone and the IS zone and calculates a ratio (RAMP ratio) of the detection zone fluorescence reading to the IS zone reading. The reader then
compares these ratios to predefined threshold limits to determine a positive or negative result for RSV in the tested sample. The instrument will
flag the test as invalid if the sample fails to migrate through the cartridge or if the IS signal is low. The test time is approximately 17 to 18 min,
including 2 to 3 min for sample preparation and a 15-min instrument time. The reader printout lists the target-specific result, kit lot number,
expiration date, test date and time, sample and user ID, and test port serial number. Kit positive and negative controls, patient results, and internal
instrument function checks are stored in the reader for easy reference. (Courtesy of 3M, reproduced with permission; originally published in
reference 6.)
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Statistical analysis. The analysis of 3MRSV results compared to DSFA and
viral culture results was performed separately for all samples that met the
inclusion criteria for G1 and G2. Analysis of the performance of 3MRSV compared to BinaxNOW was performed for all samples meeting the inclusion criteria
for G1, G2, and G3. Sensitivities, specificities, positive predictive values (PPVs),
and negative predictive values (NPVs) for 3MRSV and BinaxNOW were calculated using standard formulas and the significance between the values determined using McNemar’s test. A P value of ⬍0.05 was considered statistically
significant. Values were recalculated after discordance analysis. Because only
samples with discordant results for 3MRSV and the reference standard were
tested with ProFlu⫹, the adjusted sensitivity and specificity values can be expected to be biased high (12) and were used to resolve only potential falsenegative and false-positive 3MRSV results.

RESULTS
Sample inclusion. A total of 195 samples were not included in
the primary analysis of test performance, which required valid
reference and 3MRSV results. The reasons for exclusion included
improper sample collection (n ⫽ 2, throat swabs), culture and/or
DSFA inoculation time beyond 24 h (n ⫽ 26), one reference
method negative and one incomplete (n ⫽ 135), 3MRSV performed beyond 72 h of sample collection (n ⫽ 1), no 3MRSV
result available due to an error code most often associated with
the consistency (mucoid) of the sample (n ⫽ 27), or control
failure (n ⫽ 4). After exclusion, 1,306 (87%) of the samples (G2,
n ⫽ 1,140; G3, n ⫽ 953) gave valid results for the comparison of
3MRSV to the reference methods of DSFA and viral culture.
(The final numbers of samples per type included in the analysis
are shown in Table 2 for G1 and G2 and in Table 3 for G3).
Impact of sample characteristics on performance of 3MRSV
and the BinaxNOW test. Sample characteristics were assessed
for all 1,501 samples. Overall, 3.9% of the samples (n ⫽ 58)
were classified as bloody (50 slightly and 8 excessively). No
relationship was found between a bloody sample and the need
for retesting. Fourteen percent of the samples (n ⫽ 208) were
classified as mucoid. The percentages of mucoid samples by
sample types were 1.5% for NPS, 18.6% for NW/A, and 24.5%
for NPA. A relationship between whether a sample was mucoid or nonmucoid and the need for retesting was identified.
Primary testing using only 3MRSV yielded a significantly lower
proportion of valid test results for mucoid samples (67.3%)
than for nonmucoid samples (95.7%) (P ⬍ 0.0001). Repeat
3MRSV testing was necessary for 121 (8.1%) of the samples
(66 mucoid and 55 nonmucoid). Due to repeated invalid results with neat sample, dilution was required for 78 samples
(5.2%), of which 51 samples (24.5%) were mucoid and 27
samples (2.1%) were nonmucoid (P ⬍ 0.0001). Seventy-five of
the 78 samples were from G2 subjects. One sample was not
diluted and retested with 3MRSV due to insufficient remaining
sample. There were 43 samples that tested 3MRSV positive
after dilution, of which only 1 was considered a false positive
(DSFA and culture negative). There were 13 samples that
tested 3MRSV negative after dilution, of which 1 was DSFA
positive and therefore the 3MRSV result was considered a
false negative. Of the remaining 23 samples (16 NPA, 6 NW/A,
and 1 NPS) with invalid 3MRSV results after dilution, 15 were
positive by DSFA and/or culture. The final 3MRSV invalid
rate for mucoid samples (9.1%) was significantly higher (P ⬍
0.0001) than that for nonmucoid samples (0.3%). The overall
3MRSV invalid test rate for all samples was 1.5% (23/1,501
samples). There were initially 24 samples with invalid Binax-
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zone, and excess particles are captured at the internal standard (IS) zone. The
rapid detection reader measures the fluorescence emitted by the complexes at
the RSV and IS detection zones and calculates a ratio between the RSV and the
IS zone readings. If the 3MRSV failed, it was repeated with neat sample up to
two times. If the repeat testing failed, then the sample was diluted with an equal
volume of the viral transport medium used at the trial site and the test repeated
a final time. The result was scored as invalid if the final diluted sample did not
yield an acceptable 3MRSV result. Positive and negative controls were processed
on each day of sample testing. Each trial site performed 3MRSV using three
different lot numbers.
The total test time is approximately 17 to 18 min, including sample preparation, cartridge loading, and instrument time. A single test module contains two
ports, and a maximum of three test modules can be connected to a single reader.
Therefore, a maximum of six tests per reader can be performed at one time.
External controls. For each day of testing, the external positive and negative
kit controls were processed and tested according to the manufacturer’s instructions. Controls were repeated if an invalid result (sample error 2) was obtained.
Sample error 2 can be caused by failure of the sample to flow through the
cartridge, but it may also be caused by not using the provided assay tips, a clogged
sample pad, insufficient mixing, or interfering substances.
Primary comparator test methods. The results of the 3MRSV were compared
to those of cell culture (R-Mix [DHI], six sites; R-Mix Too [DHI], one site;
R-Mix and fibroblast tube culture, one site) and direct specimen fluorescentantibody testing (DSFA) using D3 Ultra reagents (DHI) (six sites) or Simulfluor
(Millipore, Billerica, MA) (two sites). DSFA and cell culture inoculation were
performed in accordance with the manufacturers’ instructions and each trial
site’s validated procedures within 24 h of sample collection. A sample was
considered positive for RSV if the DSFA and/or viral culture was positive and
was considered negative for RSV if both DSFA and viral culture were negative.
Secondary comparator test method. The results of the 3MRSV were also
compared to those of the BinaxNOW rapid RSV test. The BinaxNOW RSV test
was performed within 24 h of the performance of 3MRSV. Refrigerated samples
were stored at room temperature for 15 min prior to testing. BinaxNOW testing
was performed using 100 l of neat sample and according to the manufacturer’s
instructions. The BinaxNOW assay requires approximately 1 min for addition of
sample. The card is immediately sealed, and the test must be read in exactly 15
min. Samples were considered positive or negative using the same criteria as
described above for 3MRSV.
Specimen inclusion criteria for data analysis. Specimens required valid reference test data (DSFA and/or viral culture) and valid 3MRSV data to be
included in the statistical analysis. Exclusion rules for analysis for samples with
reference and 3MRSV results included the following: (i) DSFA was negative but
no culture results were available, or vice versa, and therefore this sample could
not be considered negative; (ii) DSFA or culture was performed more than 24 h
after sampling and both results were negative, since lability of RSV could have
resulted in a false-negative result; (iii) time deviations for 3MRSV results
(3MRSV was run later than 4 h after sample collection and not refrigerated); (iv)
3MRSV results were obtained in a run containing a failed control; and (v)
improper sample types (throat swabs) were tested.
Stratification of test results. 3MRSV results were compared to DSFA and
viral culture results, stratified by subject groups G1 and G2 and by sample types.
A separate comprehensive analysis of subjects ⬎22 years old (n ⫽ 166), beyond
overall sensitivity and specificity, was not statistically relevant due to the low
number of RSV-positive samples in this group (n ⫽ 10), rendering detailed
comparisons unreliable. 3MRSV results were compared to BinaxNOW RSV
results, stratified by subject groups G1, G2, and G3 and by sample type.
Testing and analysis of samples with discordant results. Further testing and
analysis were performed for 42 samples for which there was discordance between
DSFA and culture results (32 DSFA positive and culture negative, 1 DSFA
positive and culture indeterminate, 4 DSFA indeterminate and culture positive,
and 5 DSFA negative and culture positive) and for 36 samples that were deemed
to be 3MRSV false positive (culture and DSFA negative). Discordance between
the 3MRSV result and the culture, DSFA, or BinaxNOW result was resolved by
testing a frozen (⫺70°C) aliquot of the original sample with the ProFlu⫹ reverse
transcription-PCR (RT-PCR) assay (Gen-Probe/Prodesse, Waukesha, WI) after
nucleic extraction using the NucliSENS easyMAG (bioMérieux, Durham, NC).
Nucleic acid extraction and ProFlu⫹ were performed at two testing sites according to the manufacturer’s instructions. A 3MRSV negative result was considered
a true negative if the DSFA was positive and the ProFlu⫹ was negative. A
3MRSV positive result was considered a true positive if the reference tests
(DSFA and culture) were negative and the ProFlu⫹ was positive. Results of
discordance analysis were not included in the primary assessment of the 3MRSV
performance since not all samples were tested by ProFlu⫹.

3M RAPID DETECTION RSV TEST

2340

GINOCCHIO ET AL.

J. CLIN. MICROBIOL.

TABLE 1. 3MRSV assay sensitivity, specificity, positive predictive
value, and negative predictive value by subject group for
all sample types combined
Value for subject groupb:

Parametera

1

1,306
86.5 (83.0–89.3)
95.8 (94.3–97.0)
91.4
93.2
34

1,140
87.3 (83.8–90.1)
95.6 (93.8–96.9)
92.4
92.5
38

a
3MRSV sensitivity, specificity, positive PPV, and NPV were determined by
comparison to direct specimen antibody testing and/or viral culture.
b
Group 1, subjects of all ages; group 2, subjects ⬍22 years old (age group
FDA cleared for 3MRSV testing).

NOW results. Two samples did not have sufficient volume for
retesting. After retesting with BinaxNOW, 7 of the 22 remaining samples again gave invalid results, for a final BinaxNOW
invalid rate of 0.5%.
Overall performance of the 3MRSV. The performance measures of the 3MRSV for detection of RSV in all sample types
(n ⫽ 1,306) compared to a composite standard of DSFA and
viral culture for G1 (all ages) and G2 (⬍22 years old) are
shown in Table 1. Measures for G1 and G2, respectively, were
as follows: sensitivities, 86.5% and 87.3%; specificities, 95.8%
and 95.6%; PPVs, 91.4% and 92.4%; and NPVs, 93.2% and
92.5%. The sensitivity of 3MRSV for detection of RSV in
subjects ⱖ22 years old was 50%, which was significantly lower
than the sensitivity in subjects ⬍22 years old (P ⫽ 0.033) (data
not shown). The specificity of 3MRSV for the detection of
RSV in subjects ⬍22 years old was 95.6%, which was comparable to the specificity in subjects ⱖ22 years old (96.8%). The
mean performance measures were weighted by the NPA sample type (45%) for G2 subjects. For all subjects (G1), the ratio
was 20:40:40 for NW/A to NPA to NPS. Overall, there were
443 RSV-positive samples from G1 (110 NW/A, 199 NPA, and
134 NPS) and 433 RSV-positive samples from G2 (109
NPW/A, 197 NPA, and 127 NPS). Initially, there were 58
samples considered false negative when tested with 3MRSV,
including 16 DSFA-positive/culture-positive, 32 DSFA-positive/culture-negative, 1 DSFA-positive/culture-indeterminate,
4 DSFA-indeterminate/culture-positive, and 5 DSFA-negative/
culture-positive samples. Initially, there were 36 DSFA-nega-

TABLE 2. Performance of 3MRSV by subject group and sample type
Value fora:
Parameter

No. tested
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
PPV, %
NPV, %
a

Nasal washes/aspirates

Nasopharyngeal aspirates

Nasopharyngeal swabs

Group 1

Group 2

Group 1

Group 2

Group 1

Group 2

262
89.1 (0.819–0.936)

246
89.9 (0.828–0.943)

519
85.4 (0.799–0.897)

503
85.3 (0.797–0.896)

525
85.8 (0.789–0.907)

391
88.2 (0.814–0.927)

94.1 (0.891–0.969)

93.4 (0.880–0.965)

95.3 (0.924–0.971)

95.1 (0.921–0.970)

96.9 (0.947–0.982)

97.4 (0.946–0.987)

91.6
92.3

91.6
92.1

91.9
91.3

91.8
90.9

90.6
95.2

94.1
94.5

Group 1, subjects of all ages; group 2, subjects ⬍22 years old (age group FDA cleared for 3MRSV testing).
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No. tested
Sensitivity, % (95% CI)
Specificity, % (95% CI)
PPV, %
NPV, %
RSV prevalence, %

2

tive/culture-negative samples that were considered false positive when tested with 3MRSV.
Performance of the 3MRSV by specimen type. The performance measures of the 3MRSV by sample type for G1 (n ⫽
1,306) and G2 (n ⫽ 1,140) are shown in Table 2. Sensitivities
(range, 85.3% to 89.9%), specificities (range, 93.4% to 97.4%),
PPVs (range, 90.6% to 94.1%), and NPVs (range, 90.9% to
95.2%) were consistent for all specimen types and across both
age groups. The type of transport medium used did not affect
the overall performance of the 3MRSV (data not shown).
Performance of the 3MRSV by testing site. The performance
measures of the 3MRSV by testing site for all sample types
combined for subjects ⬍22 years old (G2, n ⫽ 1,140) are shown
in Table 3. The PPV and NPV calculations for each site were
determined using the respective prevalence at each site. Overall, the sensitivities ranged from 76.9% to 92.9%, specificities
from 85.4% to 98.7%, PPVs from 80.0% to 97.4%, and NPVs
from 88.2% to 94.9%. The differences in sensitivities and specificities by site were not statistically different (P ⬎ 0.3).
Overall performance of the 3MRSV after discordant-result
analysis. There were 12 samples (2 NW/A, 8 NPA, and 2 NPS)
with a positive reference test (DSFA) and a negative 3MRSV
(originally considered false negatives) that were ProFlu⫹ negative and therefore true negatives (DSFA false positive).
There were five samples (one NW/A, three NPA, and one
NPS) with negative reference tests (DSFA and culture) and a
positive 3MRSV (initially considered false positives) that were
ProFlu⫹ positive and therefore true positives. The sensitivities
and specificities of the 3MRSV marginally increased after discordance analysis for G1 (from 86.5% to 89.0% and from
95.8% to 96.4%, respectively) and for G2 (from 87.3% to
89.3% and from 95.6% to 96.3%, respectively).
Comparison of the 3MRSV to the BinaxNOW test. There
were 1,306 samples tested by both 3MRSV and BinaxNOW, of
which 7 samples had invalid BinaxNOW results (0.54%) after
repeat testing. These samples were excluded from the comparison between 3MRSV and BinaxNOW. Table 4 shows the
performance of 3MRSV compared to BinaxNOW for subjects
in G1, G2, and G3 (⬍5 years, the approved age group for
testing with BinaxNOW; n ⫽ 953). For all sample types combined in the G3 age group, 3MRSV was more sensitive than
BinaxNOW (P ⬍ 0.05); the specificities of 3MRSV and BinaxNOW were comparable (P ⫽ 0.26). When the G3 data were
sorted by individual sample types, the sensitivities of 3MRSV
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Parameter

Sensitivity (%)c

Specificity (%)d

3MRSV

BinaxNOW

3MRSV

BinaxNOW

3

NW/A
NPA
NPS
All

89.7*
85.6*
89.9*
87.9*

75.7
72.2
69.8
72.4

93.2**
96.2
98.9
96.5

100
96.2
97.8
97.6

2

NW/A
NPA
NPS
All

89.9*
85.0*
88.2*
87.2

76.2
73.1
66.9
72.0

93.3**
95.0
97.3
95.6

100
96.0
98.1
97.6

1

NW/A
NPA
NPS
All

89.1*
85.1*
85.8*
86.3*

75.5
72.8
64.2
70.8

93.9**
95.2
96.9
95.8

100
95.9
98.5
97.8

a
Group 1, subjects of all ages; group 2, subjects ⬍22 years old (age group
FDA cleared for 3MRSV testing); group 3, all subjects ⬍5 years old (age group
approved for use with the BinaxNOW RSV test).
b
NW/A, nasal wash/aspirate; NPA, nasopharyngeal aspirate; NPS nasopharyngeal swab.
c
*, 3MRSV was significantly more sensitive than BinaxNOW (P ⬍ 0.05).
d
**, 3MRSV was significantly less specific than BinaxNOW (P ⬍ 0.05).

Value for testing site:

4
5
6
7

were all significantly higher (P ⬍ 0.05) than the sensitivities of
BinaxNOW. The specificities of G3 NW/A results for 3MRSV
were significantly less (P ⬍ 0.05) than those of the BinaxNOW
results. However, the specificity of 3MRSV testing of G3 NPA
and NPS was comparable to that of BinaxNOW testing of NPA
and NPS.
It should be noted that BinaxNOW is not approved for
testing of NPA or in subjects 5 years old or older; thus, the
following G1 and G2 comparisons should be considered results
generated with off-label use of the BinaxNOW test. As shown
in Table 4, for all sample types combined and for each individual sample type, 3MRSV was significantly more sensitive
(P ⬍ 0.05) for the detection of RSV in G1 and G2 samples
than was BinaxNOW. The overall G1 and G2 3MRSV specificities were less than those for BinaxNOW, but the differences
were not statistically significant (G1, P ⫽ 0.15; G2, P ⫽ 0.31).
The specificities of NW/A results for 3MRSV were significantly less (P ⬍ 0.05) than those for BinaxNOW. However, the
specificities of 3MRSV testing of NPA and NPS were comparable to those of BinaxNOW testing of NPA and NPS.
External control performance. Overall, results were available for 249 positive and 249 negative controls. All negative
controls were 3MRSV negative, and 247/249 (99.2%) of the
positive controls were 3MRSV positive. Seventeen controls
(3.6%) resulted in sample error 2, which related to a failure to
detect sample in the cartridge. Sixteen of the 17 controls were
processed at two sites using the same lot of M4 medium.

8

83
92.9 (0.810–0.975)
85.4 (0.716–0.931)
96.7
92.1

DISCUSSION
The 3MRSV demonstrated overall good performance for
the detection of RSV in all three samples types (NPW/A, NPA,
and NPS) collected from symptomatic subjects of all ages combined (86.5% sensitivity and 95.8% specificity). Both the sensitivity and specificity of 3MRSV increased when samples with
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3

77
166
88.0 (0.700–0.958) 79.6 (0.671–0.882)
98.1 (0.899–0.997) 93.8 (0.877–0.969)
95.7
86.0
94.4
90.5

TABLE 3. 3MRSV performance by testing site for subjects ⬍22 years old and for all sample types combined

2

90
135
178
182
83.3 (0.641–0.933) 76.9 (0.579–0.890) 89.8 (0.822–0.944) 88.4 (0.799–0.936)
95.5 (0.875–0.984) 95.4 (0.897–0.980) 93.8 (0.862–0.973) 97.9 (0.927–0.994)
87.0
80.0
94.6
97.4
94.0
94.5
88.2
90.4

Sample
typeb

Groupa

1

No. tested
229
Sensitivity, % (95% CI) 89.7 (0.810–0.947)
Specificity, % (95% CI) 98.7 (0.953–0.996)
PPV, %
97.2
NPV, %
94.9

TABLE 4. Comparisons of the sensitivities and specificities of the
3MRSV and BinaxNOW RSV by subject group and
by sample type
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FDA for testing with BinaxNOW. Similar results were found in
a study by Borek et al. which compared BinaxNOW RSV
results to those of DSFA and/or tissue culture in nasopharyngeal aspirate and wash samples from children and adults (1).
The sensitivity and specificity of BinaxNOW were 74% and
100%, respectively. A study by Cruz et al. that compared
BinaxNOW to viral culture for 14,756 pediatric respiratory
specimens demonstrated a sensitivity of 81% and a specificity
of 93.2% for BinaxNOW (3).
The observation of enhanced sensitivity of the 3MRSV over
the BinaxNOW test was consistent with a previous study that
demonstrated that the 3M Rapid Detection Influenza A⫹B
test (3MA⫹B) was significantly (P ⬍ 0.001) more sensitive
than the BinaxNOW influenza A&B test for the detection of
both influenza A and B viruses (6). The significantly better
sensitivities of the 3MRSV and 3MA⫹B compared to the
BinaxNOW tests may be due to the enhanced detection format
and more consistent interpretation of results. False-positive
results were found with both the BinaxNOW and 3MRSV, as
noted with the 3MA⫹B. The specificities of 3MRSV for NPA
and NPS were comparable to those of BinaxNOW, but for
NW/A the specificity of 3MRSV was significantly less than that
of the BinaxNOW RSV test.
One of the major benefits of the 3MRSV was the use of
instrumentation to read and interpret test results. Generally,
rapid antigen tests require little technical expertise; however,
the result relies on user interpretation that can be subjective
and can lead to errors. Automation of these processes should
reduce the risk of user misinterpretation. Finally, the rapid
detection reader provides a variety of printouts, such as instrument function checks, control results, lot numbers, reagent
expiration dates, and patient results, that can be used to document quality control and help laboratories meet their various
quality assurance obligations.
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